Alnylam Pharmaceuticals
ALNYAlnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2022-2024
All insider trades at Alnylam Pharmaceuticals
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 2/29/2024 | Sell | Sharp, Phillip A. | Director | $153.1 | $4,540,072 |
| 2/28/2024 | Sell | Franchini, Indrani Lall | EVP, CLO & Secretary | $156.4 | $51,095 |
| 2/28/2024 | Sell | Garg, Pushkal | CMO & EVP Dev & Med Affairs | $156.4 | $89,144 |
| 2/28/2024 | Sell | Greenstreet, Yvonne | Chief Executive Officer | $156.4 | $455,357 |
| 2/28/2024 | Sell | Poulton, Jeffrey V. | EVP, Chief Financial Officer | $156.4 | $89,144 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)